Structural, molecular, and functional insights into Schlafen proteins

참고문헌 (95)

1. Graham, G. J., "Tandem genes and clustered genes", J. Theor. Biol, 175, pp.71~87 (1995)
2. Yang, J. Y., "Structure of Schlafen13 reveals a new class of tRNA", rRNAtargeting RNase engaged in translational control, 2018, pp.9, 1165~
3. Bustos, O., "Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence", Gene, 447, pp.1~11 (2009)
4. Schwarz, D. A., "Schlafen, a new family of growth regulatory genes that affect thymocyte development", Immunity, 9, pp.657~668 (1998)
5. Geserick, P., "Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif", Int. Immunol, 16, pp.1535~1548 (2004)
6. Bell, T. A., "The paternal gene of the DDK syndrome maps to the Schlafen gene cluster on mouse chromosome 11", Genetics, 172, pp.411~423 (2006)
7. Neumann, B., "Subcellular localization of the Schlafen protein family", Biochem. Biophys. Res. Commun, 370, pp.62~66 (2008)
8. van Zuylen, W. J., "Macrophage activation and differentiation signals regulate schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis", PLoS ONE, 6, pp.e15723~ (2011)
9. Liu, F., "The Schlafen family: complex roles in different cell types and virus replication", Cell Biol. Int, 42, pp.2~8 (2018)
10. de la Casa-Esperon, E., "From mammals to viruses: the Schlafen genes in developmental, proliferative and immune processes", Biomol. Concepts, 2, pp.159~169 (2011)
11. Mavrommatis, E., "The schlafen family of proteins and their regulation by interferons", J. Interferon Cytokine Res, 33, pp.206~210 (2013)
12. Murai, J., "Schlafen 11(SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies", Pharmacol. Ther, 201, pp.94~102 (2019)
13. Gubser, C., "Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence", J. Gen. Virol, 88, pp.1667~1676 (2007)
14. Garvie, C. W., "Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase", Nat. Commun, 12, pp.4375~ (2021)
15. Wiese, C., "Disparate requirements for the Walker A and B ATPase motifs of human RAD51D in homologous recombination", Nucleic Acids Res, 34, pp.2833~2843 (2006)
16. Fletcher, S. J., "SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects", J. Clin. Invest, 125, pp.3600~3605 (2015)
17. Murai, J., "SLFN11 blocks stressed replication forks independently of ATR", Mol. Cell, 69, pp.371~384.e376 (2018)
18. Murai, Y., "SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243", Cancer Res, 81, pp.3067~3078 (2021)
19. Li, M., "Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11", Nature, 491, pp.125~128 (2012)
20. Luna, A., "CellMiner cross-database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics", Nucleic Acids Res, 49, pp.D1083~D1093 (2021)
21. Li, M., "DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs", Nat. Struct. Mol. Biol, 25, pp.1047~1058 (2018)
22. Chen, J., "Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells", Nat. Commun, 12, pp.6204~ (2021)
23. Metzner, F. J., "Structural and biochemical characterization of human Schlafen 5", Nucleic Acids Res, 50, pp.1147~1161 (2022)
24. Pisareva, V. P., "Characterization of novel ribosome-associated endoribonuclease SLFN14 from rabbit reticulocytes", Biochemistry, 54, pp.3286~3301 (2015)
25. Tao Yue, "SLFN2 protection of tRNAs from stress-induced cleavage is essential for T cell–mediated immunity", Science, 372(6543) (2021), American Association for the Advancement of Science (AAAS)[DOI]
26. Li, D., "Estrogen-related hormones induce apoptosis by stabilizing Schlafen-12 protein turnover", Mol. Cell, 75, pp.1103~1116.e1109 (2019)[DOI]
27. Zhou, C., "SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway", Theranostics, 10, pp.4627~4643 (2020)
28. Chun Zhou, "Dna2 nuclease-helicase structure, mechanism and regulation by Rpa", eLife, 4 (2015), eLife Sciences Publications, Ltd[DOI]
29. Kelley, L. A., "The Phyre2 web portal for protein modeling, prediction and analysis", Nat. Protoc, 10, pp.845~858 (2015)
30. Mu, Y., "SLFN11 inhibits checkpoint maintenance and homologous recombination repair", EMBO Rep, 17, pp.94~109 (2016)
31. Okamoto, Y., "SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells", Blood, 137, pp.336~348 (2021)
32. Guo, G., "Human Schlafen 11 exploits codon preference discrimination to attenuate viral protein synthesis of prototype foamy virus(PFV)", Virology, 555, pp.78~88 (2021)
33. Federico Valdez, "Schlafen 11 Restricts Flavivirus Replication", Journal of Virology, 93(15) (2019), American Society for Microbiology[DOI]
34. Seong, R. K., "Schlafen 14 (SLFN14) is a novel antiviral factor involved in the control of viral replication", Immunobiology, 222, pp.979~988 (2017)
35. Kim, E. T., "Comparative proteomics identifies Schlafen 5(SLFN5)as a herpes simplex virus restriction factor that suppresses viral transcription", Nat. Microbiol, 6, pp.234~245 (2021)
36. Arslan, A. D., "Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma", Oncogene, 36, pp.6006~6019 (2017)
37. Wan, G., "Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription", Br. J. Cancer, 123, pp.633~643 (2020)
38. Linder, P., "From unwinding to clamping-the DEAD box RNA helicase family", Nat. Rev. Mol. Cell Biol, 12, pp.505~516 (2011)
39. Bourgeois, C. F., "The multiple functions of RNA helicases as drivers and regulators of gene expression", Nat. Rev. Mol. Cell Biol, 17, pp.426~438 (2016)
40. O’Donnell, M. E., "The ring-shaped hexameric helicases that function at DNA replication forks", Nat. Struct. Mol. Biol, 25, pp.122~130 (2018)
41. Bohm, S., "The role of post-translational modifications in finetuning BLM helicase function during DNA repair", DNA Repair, 22, pp.123~132 (2014)
42. Li, Z., "Post-translational modifications of the mini-chromosome maintenance proteins in DNA replication", Genes, 10, pp.331~ (2019)
43. Malone, D., "Dephosphorylation activates the interferon-stimulated Schlafen family member 11 in the DNA damage response", J. Biol. Chem, 294, pp.14674~14685 (2019)
44. Bo Yan, "Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death", Cell Chemical Biology, 29(6), pp.958~969.e5 (2022), Elsevier BV[DOI]
45. Fletcher, S. J., "Role of the novel endoribonuclease SLFN14 and its diseasecausing mutations in ribosomal degradation", RNA, 24, pp.939~949 (2018)
46. Bruno Hernáez, "Viral cGAMP nuclease reveals the essential role of DNA sensing in protection against acute lethal virus infection", Science Advances, 6(38) (2020), American Association for the Advancement of Science (AAAS)[DOI]
47. Murai, J., "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition", Oncotarget, 7, pp.76534~76550 (2016)
48. Jo, U., "Precision oncology with drugs targeting the replication stress, ATR, and Schlafen 11", Cancers, 13, pp.4601~ (2021)
49. Redon, C. E., "gamma-H2AX and other histone post-translational modifications in the clinic", Biochim. Biophys. Acta, 1819, pp.743~756 (2012)
50. Ukhyun Jo, "SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR", CHK1 inhibitors, 2021, pp.118(6), ~[DOI]
51. Murai, J., "Chromatin remodeling and immediate early gene activation by SLFN11 in response to replication stress", Cell Rep, 30, pp.4137~4151.e4136 (2020)
52. Zoppoli, G., "Putative DNA", RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents, 2012, pp.109, 15030~15035
53. Barretina, J., "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity", Nature, 483, pp.603~607 (2012)
54. Zhang, B., "A wake-up call for cancer DNA damage : the role of Schlafen 11(SLFN11)across multiple cancers", Br. J. Cancer, 125, pp.1333~1340 (2021)
55. Lok, B. H., "PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer", Clin. Cancer Res, 23, pp.523~535 (2017)
56. Kagami, T., "The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy", BMC Cancer, 20, pp.1123~ (2020)
57. Kang, M. H., "Activity of MM-398, nanoliposomal irinotecan(nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression", Clin. Cancer Res, 21, pp.1139~1150 (2015)
58. Deng, Y., "High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatinbased treatment", BMC Cancer, 15, pp.833~ (2015)
59. Pietanza, M. C., "Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsedsensitive or refractory small-cell lung cancer", J. Clin. Oncol, 36, pp.2386~2394 (2018)
60. Isnaldi, E., "Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer", Breast Cancer Res. Treat, 177, pp.335~343 (2019)
61. Lee, T. W., "Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia", Int. J. Radiat. Biol, 95, pp.1597~1612 (2019)
62. Conteduca, V., "SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy", Mol. Cancer Ther, 19, pp.1157~1164 (2020)
63. Lheureux, S., "EVOLVE : a multicenter open-label single-arm clinical and translational phase II Trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression", Clin. Cancer Res, 26, pp.4206~4215 (2020)
64. Ramkumar, K., "AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors", Mol. Cancer Res, 19, pp.485~497 (2021)
65. Takashima, T., "Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers", Br. J. Cancer, 125, pp.65~77 (2021)
66. Gartrell, J., "SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA-damaging agents", Mol. Cancer Ther, 20, pp.2151~2165 (2021)
67. Jones, P. A., "The epigenomics of cancer", Cell, 128, pp.683~692 (2007)
68. Nogales, V., "Epigenetic inactivation of the putative DNA", RNA helicase SLFN11 in human cancer confers resistance to platinum drugs, 2016, pp.7, 3084~3097
69. He, T., "Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer", Epigenomics, 9, pp.849~862 (2017)
70. Gardner, E. E., "Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis", Cancer Cell, 31, pp.286~299 (2017)
71. Tang, S. W., "Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11(SLFN11)expression with class I histone deacetylase inhibitors", Clin. Cancer Res, 24, pp.1944~1953 (2018)
72. Takashima, T., "Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq", Virchows Arch, 478, pp.569~579 (2021)
73. Qu, S., "Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers", J. Thorac. Oncol, 17, pp.141~153 (2022)
74. Mao, S., "Resistance to pyrrolobenzodiazepine dimers is associated with SLFN11 downregulation and can be reversed through inhibition of ATR", Mol. Cancer Ther, 20, pp.541~552 (2021)
75. Florence Coussy, "BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers", Science Translational Medicine, 12(531) (2020), American Association for the Advancement of Science (AAAS)[DOI]
76. Jo, U., "Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents", Mol. Cancer Ther, 20, pp.1431~1441 (2021)
77. Murai, Y., "Schlafen 11 expression in human acute leukemia cells with gain-offunction mutations in the interferon-JAK signaling pathway", iScience, 24, pp.103173~ (2021)
78. Tang, S. W., "SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing Sarcoma", Clin. Cancer Res, 21, pp.4184~4193 (2015)
79. Katsoulidis, E., "Role of interferon {alpha}(IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells", J. Biol. Chem, 285, pp.40333~40341 (2010)
80. Sassano, A., "Human Schlafen 5(SLFN5)is a regulator of motility and invasiveness of renal cell carcinoma cells", Mol. Cell Biol, 35, pp.2684~2698 (2015)
81. Wan, G., "SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT", GSK-3beta, Cell. Signal, pp.2019, 59[DOI]
82. Gu, X., "SLFN5 influences proliferation and apoptosis by upregulating PTEN transcription via ZEB1 and inhibits the purine metabolic pathway in breast cancer", Am. J. Cancer Res, 10, pp.2832~2850 (2020)
83. Companioni Napoles, O., "SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer", J. Gastroenterol, 52, pp.39~49 (2017)
84. Martinez, R. S., "SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer", Cancer Res, 81, pp.3664~3678 (2021)
85. de Waal, L., "Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics", Nat. Chem. Biol, 12, pp.102~108 (2016)
86. Vandenberghe, P., "Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST)", Oncotarget, 8, pp.41026~41043 (2017)
87. Nazir, M., "Targeting tumor cells based on phosphodiesterase 3A expression", Exp. Cell Res, 361, pp.308~315 (2017)
88. An, R., "PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth", Am. J. Cancer Res, 9, pp.1905~1921 (2019)
89. Lewis, T. A., "Optimization of PDE3A modulators for SLFN12-dependent cancer cell killing", ACS Med. Chem. Lett, 10, pp.1537~1542 (2019)
90. Ai, Y., "An alkaloid initiates phosphodiesterase 3A-schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity", Nat. Commun, 11, pp.3236~ (2020)
91. Sarmad Al-Marsoummi, "Schlafen 12 Is Prognostically Favorable and Reduces C-Myc and Proliferation in Lung Adenocarcinoma but Not in Lung Squamous Cell Carcinoma", Cancers, 12(10), pp.2738~ (2020), MDPI AG[DOI]
92. Kovalenko, P. L., "Schlafen 12 expression modulates prostate cancer cell differentiation", J. Surg. Res, 190, pp.177~184 (2014)
93. Al-Marsoummi, S., "Schlafen12 reduces the aggressiveness of triple negative breast cancer through post-transcriptional regulation of ZEB1 that drives stem cell differentiation", Cell Physiol. Biochem, 53, pp.999~1014 (2019)
94. Ding, L., "MiR130b from Schlafen4(+)MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer", Gut, 69, pp.1750~1761 (2020)
95. Merchant, J. L., "Hedgehog signaling links chronic inflammation to gastric cancer precursor lesions", Cell. Mol. Gastroenterol. Hepatol, 3, pp.201~210 (2017)

관련 논문AI추천